Phase 3 Recruiting Network
This phase III trial evaluates whether a web-based intervention called Current Together after Cancer (CTAC) works to increase the number of patients with surgically removed (resected) colorectal cancer who receive surveillance care that al…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT07018869
Locations: - Anchorage Associates in Radiation Medicine — Anchorage, Alaska
- Alaska Breast Care and Surgery LLC — Anchorage, Alaska
- Alaska Oncology and Hematology LLC — Anchorage, Alaska
+ 373 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, oxalipl…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06662786
Locations: - Banner MD Anderson Cancer Center — Gilbert, Arizona
- St. Bernard's Medical Center — Jonesboro, Arkansas
- Highlands Oncology Group — Springdale, Arkansas
+ 78 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of standard-of-care chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite stable colorectal cancer.
Sponsor: Incyte Corporation
NCT ID: NCT07284849
Locations: - Mitchell Cancer Institute — Mobile, Alabama
- The University of Arizona Cancer Center — Tucson, Arizona
- Roche Tissue Diagnostics, Companion Diagnostics — Tucson, Arizona
+ 72 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fl…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06750094
Locations: - Ironwood Cancer and Research Center — Chandler, Arizona
- Banner MD Anderson Cancer Center — Gilbert, Arizona
- Arizona Oncology Associates PC NAHOA — Prescott, Arizona
+ 68 more sites in the U.S.
Phase 3 Recruiting Network
This phase III trial compares hepatic arterial infusion (HAI) (pump chemotherapy) in addition to standard of care chemotherapy versus standard of care chemotherapy alone in treating patients with colorectal cancer that has spread to the li…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT05863195
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Banner MD Anderson Cancer Center — Gilbert, Arizona
- Banner-University Medical Center Phoenix — Phoenix, Arizona
+ 59 more sites in the U.S.
Phase 3 Recruiting Industry
The primary purpose of this study is to evaluate the efficacy of perioperative dostarlimab compared with standard of care (SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instab…
Sponsor: GlaxoSmithKline
NCT ID: NCT05855200
Locations: - GSK Investigational Site — Tucson, Arizona
- GSK Investigational Site — Los Angeles, California
- GSK Investigational Site — New Haven, Connecticut
+ 46 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untreated, unresectable, or metastatic color…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07221357
Locations: - Local Institution - 0428 — Tucson, Arizona
- Highlands Oncology Group — Springdale, Arkansas
- USC/Norris Comprehensive Cancer Center — Los Angeles, California
+ 43 more sites in the U.S.
Phase 3 Recruiting Industry
Researchers are looking for other ways to treat locally advanced or metastatic colorectal cancer (mCRC) that is unresectable and has a gene mutation called KRAS G12C. Standard (or usual) treatments for this type of colorectal cancer may in…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06997497
Locations: - Mayo Clinic - Arizona ( Site 0090) — Phoenix, Arizona
- Orange Coast Memorial Medical Center ( Site 2007) — Fountain Valley, California
- Los Angeles Hematology Oncology Medical Group ( Site 0084) — Los Angeles, California
+ 41 more sites in the U.S.
Phase 3 Recruiting Industry
This study aims to address the unmet medical need of participants with metastatic colorectal cancer (mCRC) who have previously been treated with irinotecan, oxaliplatin, a fluoropyrimidine, and bevacizumab, by demonstrating an overall surv…
Sponsor: EMD Serono Research & Development Institute, Inc.
NCT ID: NCT07549412
Locations: - Rocky Mountain Cancer Centers, LLP- Aurora — Lone Tree, Colorado
- Florida Cancer Specialists-Broadway — Fort Myers, Florida
- Florida Cancer Specialists - St. Petersburg Bayfront — St. Petersburg, Florida
+ 16 more sites in the U.S.
Phase 3 Recruiting Industry
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess the adverse events and change in disease activity of telisotuzumab adizutecan plus bevacizumab compared to standard…
Sponsor: AbbVie
NCT ID: NCT07525206
Locations: - City Of Hope - Phoenix /ID# 279450 — Goodyear, Arizona
- Highlands Oncology Group - Springdale /ID# 279444 — Springdale, Arkansas
- City of Hope National Medical Center /ID# 279449 — Duarte, California
+ 15 more sites in the U.S.
Phase 3 Recruiting Academic/Other
Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.
Sponsor: Johns Hopkins University
NCT ID: NCT02000089
Locations: - Yale University — New Haven, Connecticut
- Johns Hopkins Hospital — Baltimore, Maryland
- Dana Farber Cancer Center, Harvard University — Boston, Massachusetts
+ 6 more sites in the U.S.
Phase 3 Recruiting Industry
The performance of SGM-101, an intraoperative imaging agent, will be compared to that of standard "white light" visualization during surgical resections of colorectal cancer.
Sponsor: Surgimab
NCT ID: NCT03659448
Locations: - City of Hope National Medical Center — Duarte, California
- Moores Cancer Center - UCSD Health — La Jolla, California
- Cleveland Clinic Florida — Weston, Florida
+ 3 more sites in the U.S.